Case Report
BibTex RIS Cite

Erişkin Still Hastalığı Öntanısı İle Takip Edilen Hastada Moksifloksasin Kullanımı Sonrası Gelişen Hiponatremi Ve Hiperkalemi: Vaka Sunumu

Year 2020, Volume: 10 Issue: 2, 317 - 321, 15.06.2020
https://doi.org/10.31832/smj.714365

Abstract

Moksifloksasin, kinolon grubu bir antibiyotiktir ve yatan hastalarda kullanım sıklığı her geçen gün artmaktadır. Bu antibiyotik için bildirilen yan etkiler arasında mide bulantısı, kusma, karın ağrısı, baş ağrısı, hipoglisemi veya hiperglisemi, anemi, artralji, kas ağrısı ve tendon rüptürü vardır. Elektrolit dengesizliği ile ilgili yan etkiler literatürde nadiren bildirilmiştir. Akciğer grafisinde akciğer sağ bazal bölgede görülen infiltrasyon alanına yönelik profilaktik moksifloksasin tedavisi başlandı. Hastanın plazma sodyum (Na) seviyesi tedavinin beşinci gününde 129 (135-145) mEq / L’ye düşmüş, potasyum (K) seviyesi tedavinin beşinci gününde 5,8 (3.5-5.5) mmol / L'ye yükselmiştir. Kan ve idrar kültürü test sonuçları negatif olarak sonuçlanmasıyla moksifloksasin tedavisi 5. gününde kesildi. Tedavinin kesilmesinden üç gün sonra Na ve K seviyeleri normal seviyelere ulaştı. Bu durum, hiperkalemi ve hiponatreminin moksifloksasin tedavisinin bir yan etkisi olabileceğini düşündürdü. Moksifloksasin tedavisi sırasında hiponatremi ve / veya hiperkalemi ortaya çıkarsa, yan etkiler düşünülmeli ve tedavi derhal kesilmelidir.

References

  • 1.Günal E, Erdem H. Kinolonlar. İç Hastalıkları Dergisi. 2014; 21: 69-85.
  • 2.Sanjith S, Raodeo A, Clerk A, Pandit R, Karnad D.R. Moxifloxacin-induced rhabdomyolysis. Intensive Care Medicine. 2012; 38: 725.
  • 3.Yamaguchi M, Ohta A, Tsunematsu T. Preliminary criteria for classification of adult Still's disease. Journal of Rheumatology. 1992; 19(3): 424–430.
  • 4.Kang J, Wang L, Chen XL, Triggle DJ, Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol. 2001; 59: 122.
  • 5.Müssig K, Schnauder G, Mörike K. Severe and symptomatic hyponatremia after moxifloxacin intake. Netherlands Journal of Medicine. 2009; 67(5): 197.,
  • 6-Felix K.Y, Satish A.E. Syndrome of inappropriate antidiuretic hormone associated with moxifloxacin. American Journal of Health-System Pharmacy. 2012; 69(3): 217–220. 
  • 7.Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York. 2001; 900.
  • 8. Adler D, Voide C, Thorens JB, Desmeules J. SIADH consecutive to ciprofloxacin intake. Europan Journal of Internal Medicine. 2004; 15(7): 463-464.

Hyponatremia And Hyperkalemia Caused By Moxifloxacin Use In A Patient Followed With Prediagnosıs Of Adult Still’s Disease: A Case Report

Year 2020, Volume: 10 Issue: 2, 317 - 321, 15.06.2020
https://doi.org/10.31832/smj.714365

Abstract

Moxifloxacin is an antibiotic of quinolone group and its usage frequency for inpatients increases day by day. Reported side effects for this antibiotic include nausea, vomiting, stomachache, headache, hypoglycemia or hyperglycemia, anemia, arthralgia, myalgia and tendon rupture. Solely, side effects regarding electrolyte imbalance are rarely reported. Since an infiltration in the right basal region of the lung was found on chest X-ray, prophylactic moxifloxacin was started. The plasma sodium (Na) level of the patient decreased to 129 (135-145) mEq/L on the fifth day of the treatment while the potassium (K) level increased to 5,8 mmol/L on the fifth day of the treatment. When blood and urine culture test results came out as negative, moxifloxacin treatment was discontinued on its 5th day. Three days after the discontinuation, Na and K levels reached to normal levels. This situation made us think that hyperkalemia and hyponatremia occurred as a side effect of moxifloxacin treatment. If hyponatremia and/or hyperkalemia occurs during treatment of moxifloxacin, adverse effects must be thought and the treatment must be discontinued immediately.

References

  • 1.Günal E, Erdem H. Kinolonlar. İç Hastalıkları Dergisi. 2014; 21: 69-85.
  • 2.Sanjith S, Raodeo A, Clerk A, Pandit R, Karnad D.R. Moxifloxacin-induced rhabdomyolysis. Intensive Care Medicine. 2012; 38: 725.
  • 3.Yamaguchi M, Ohta A, Tsunematsu T. Preliminary criteria for classification of adult Still's disease. Journal of Rheumatology. 1992; 19(3): 424–430.
  • 4.Kang J, Wang L, Chen XL, Triggle DJ, Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol. 2001; 59: 122.
  • 5.Müssig K, Schnauder G, Mörike K. Severe and symptomatic hyponatremia after moxifloxacin intake. Netherlands Journal of Medicine. 2009; 67(5): 197.,
  • 6-Felix K.Y, Satish A.E. Syndrome of inappropriate antidiuretic hormone associated with moxifloxacin. American Journal of Health-System Pharmacy. 2012; 69(3): 217–220. 
  • 7.Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York. 2001; 900.
  • 8. Adler D, Voide C, Thorens JB, Desmeules J. SIADH consecutive to ciprofloxacin intake. Europan Journal of Internal Medicine. 2004; 15(7): 463-464.
There are 8 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Articles
Authors

Kubilay İşsever

Erkut Etçioğlu 0000-0002-8117-7929

Emel Gönüllü

Publication Date June 15, 2020
Submission Date April 3, 2020
Published in Issue Year 2020 Volume: 10 Issue: 2

Cite

AMA İşsever K, Etçioğlu E, Gönüllü E. Hyponatremia And Hyperkalemia Caused By Moxifloxacin Use In A Patient Followed With Prediagnosıs Of Adult Still’s Disease: A Case Report. Sakarya Tıp Dergisi. June 2020;10(2):317-321. doi:10.31832/smj.714365

https://i.creativecommons.org/l/by-nc-sa/4.0/88x31.png 

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.